Nisa Investment Advisors LLC Sells 87,388 Shares of Becton, Dickinson and Company (NYSE:BDX)

Nisa Investment Advisors LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 55.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,950 shares of the medical instruments supplier's stock after selling 87,388 shares during the quarter. Nisa Investment Advisors LLC's holdings in Becton, Dickinson and Company were worth $16,023,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. grew its holdings in Becton, Dickinson and Company by 1.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock valued at $694,000 after buying an additional 50 shares in the last quarter. Northcape Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 0.5% during the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after purchasing an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 5.7% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after purchasing an additional 53 shares in the last quarter. Brady Family Wealth LLC grew its holdings in shares of Becton, Dickinson and Company by 1.2% during the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after purchasing an additional 53 shares in the last quarter. Finally, Diversified Trust Co grew its holdings in shares of Becton, Dickinson and Company by 4.7% during the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after purchasing an additional 53 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Down 0.9%

Becton, Dickinson and Company stock traded down $1.63 during trading hours on Friday, hitting $175.87. The stock had a trading volume of 2,428,716 shares, compared to its average volume of 2,078,243. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. The stock has a market cap of $50.41 billion, a price-to-earnings ratio of 33.56, a P/E/G ratio of 1.34 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The business's 50 day simple moving average is $172.33 and its 200-day simple moving average is $206.06.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating the consensus estimate of $3.28 by $0.07. The firm had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business's quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the company earned $3.17 earnings per share. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were given a $1.04 dividend. The ex-dividend date was Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.37%. Becton, Dickinson and Company's dividend payout ratio is presently 79.39%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BDX. Bank of America lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a report on Thursday, May 1st. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their target price for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Morgan Stanley reduced their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Piper Sandler downgraded Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $260.00 to $185.00 in a research report on Friday, May 2nd. Finally, Barclays dropped their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.